Business Wire

Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer

Share

Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis.

Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life. The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer.

“Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we offer a compelling combination of capabilities,” said Simon Read, Founder and CEO, Mariana Oncology. “In the short time since founding the company, the team at Mariana Oncology has developed a leading radiopharmaceutical discovery platform and an innovative pipeline. Our strategy has centered on overcoming the unique challenges of end-to-end radiopharmaceutical R&D and ultimately, delivery of these drugs to the bedside. Both Mariana and Novartis are committed to transforming cancer care, and together we will be in a better position to do that.”

“This acquisition of Mariana Oncology brings to Novartis phenomenal talent and new capabilities in radioligand therapeutic research that complement our wide-ranging internal research and drug discovery efforts, in addition to our translational and clinical development capabilities,” said Shiva Malek, PhD, Global Head of Oncology for Biomedical Research at Novartis. “This is an ideal pairing, and we are thrilled to continue to do pioneering science together, translating RLT discovery into clinical development to deliver transformative therapies to patients.”

Mariana was founded in 2021 by Atlas Venture, Access Biotechnology and RA Capital Management, and has raised additional funds from other top investors including DeepTrack Capital and Forbion.

The transaction is subject to customary closing conditions.

Centerview Partners LLC served as financial advisor, and Goodwin Procter as legal counsel to Mariana Oncology on the transaction.

About Mariana Oncology
Mariana Oncology is a fully integrated, radiopharmaceutical company pioneering a new standard of care in cancer treatment – targeted peptide-based radioligand therapeutics (RLTs) designed to maximize tumor penetration while minimizing toxicity. Mariana is comprised of some of the world’s leading experts in radiopharmaceutical science and manufacturing who together are pioneering innovations in end-to-end discovery, development and delivery of radioligand therapeutics. The company has developed a portfolio of novel RLTs designed to target a broad range of difficult-to-treat cancers. Mariana’s lead program, MC-339, is an actinium-based radioligand therapeutic being investigated to treat small cell lung cancer.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
media@marianaoncology.com

Investors:
Chris Brinzey, ICR Westwicke
chris.brinzey@westwicke.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare4.12.2024 16:58:00 CET | Press Release

Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of “The Hive”, a novel scientific research hub located at its R&D centre in Barcelona, Spain. The Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s scientists, creating a unique innovation ecosystem that is aimed at advancing scientific breakthroughs and enhancing research success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204100180/en/ From left upper row, to right: Marc Soriano, R&D Project Portfolio and Partnership, Lidia Martín, General Manager of Almirall Iberia, Antonio Gallardo, Jorge Gallardo, Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, Meritxell Granell, Director of Institutional Relations, Raquel Yotti, PERTE Commissioner for Vanguard Health, Olga Pané, Consellera de Salut, Lourdes Borrell, Mayoress of Sant Feliu de Llobre

Now Is the Time To Host Events in Japan, With the Yen at a Low! Global Produce Launches Full-Scale Production of “Event Hosting in Japan” for Overseas Companies4.12.2024 16:00:00 CET | Press Release

Global Produce Co., Ltd. (Head Office: Shibuya Ward, Tokyo; CEO: Masaki Kouhata; hereinafter referred to as “Global Produce”), a company specializing in event production, is pleased to announce the full-scale launch of its production services for overseas companies looking to host events in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121186571/en/ Global Produce Launches Full-Scale Production of “Event Hosting in Japan” for Overseas Companies (Graphic: Business Wire) With Global Produce, your dream event in Japan can become a reality! Our “Japan Event Hosting Plan” was created to bring the visions of overseas companies to life using events hosted in Japan. Not only will native speakers be present at the forefront, but our producers, with over 30 years of experience, will accompany you every step of the way. They utilize their extensive expertise and innovative creativity, using the latest technologies to create

DataXstream Launches OMS+ Cloud for SAP S/4HANA Cloud Public Edition4.12.2024 15:03:00 CET | Press Release

DataXstream LLC, an SAP® Endorsed app and Gold-level partner developing innovative solutions for SAP sales and distribution, today introduced OMS+ Cloud for SAP S/4HANA Cloud Public Edition. OMS+ has streamlined complex sales and order processes for SAP users for over a decade within SAP ECC and S/4HANA Cloud Private Edition environments. But recent forecast numbers from Gartner show that worldwide spending on public cloud services is increasing significantly and will reach a total of $723.4 billion in 2025, with a 19% growth increase in Cloud Application Services (SaaS). (Source: Gartner, November 2024) DataXstream’s OMS+ Cloud will now extend its award-winning OMS+ platform by delivering end-to-end point of sales (POS) and order management capabilities for SAP Public Cloud. OMS+ Cloud will simplify complex POS, quote and order processes often associated with vertically integrated retail, wholesale distribution and manufacturing environments. OMS+ Cloud offers POS core capabilities su

Andersen Global Solidifies Presence in Malta with Member Firm Addition4.12.2024 15:00:00 CET | Press Release

Andersen Global continues to strengthen its presence in Europe through the establishment of Andersen in Malta. Together, with existing member law firm Chetcuti Cauchi Advocates, the firms will provide a comprehensive suite of integrated tax, legal, and corporate services to private and business clients in Malta and internationally. Andersen in Malta provides a wide range of services, including personal and corporate tax advisory and tax compliance services, transfer pricing, data compliance, global mobility and HNW immigration, estate planning, private wealth structuring, family business advisory and business advisory services. The firm specializes in navigating complex regulatory and tax frameworks and advises high-net-worth individuals, family offices, and multinational businesses. “As Malta evolves as a reliable destination for private wealth structuring and business expansion in Europe, our firms remain committed to providing quality, client-focused services,” said Jean-Philippe Ch

Europe’s Most Advanced Weather Satellite Is Now Fully Operational4.12.2024 14:26:00 CET | Press Release

The first of EUMETSAT’s Meteosat Third Generation (MTG) satellites became fully operational today. MTG-Imager 1 also receives a new name – Meteosat-12 – to mark the occasion. The two main instruments on board Meteosat-12, the Flexible Combined Imager (FCI) and the Lightning Imager (LI), play a crucial role in enabling meteorological services to help protect lives and livelihoods by providing high-resolution, accurate data for predicting severe weather events. Data from Meteosat-12’s instruments are now being disseminated to national meteorological services and others for operational use and are expected to have a significant impact on weather forecasting and understanding of our climate. “MTG is one of the most innovative and complex meteorological satellite systems ever built,” EUMETSAT Director-General Phil Evans said. “We have been working with our member states’ meteorological services to ensure they can make the best use of the data, which is essential for one of the main challeng

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye